01-06-2017 12:19 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
09-05-2017 07:45 CET Three-month interim report (Q1) 2017
04-05-2017 21:07 CET ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada
03-05-2017 10:28 CET Release date of three-month interim report (Q1) 2017 and audio cast
16-04-2017 20:00 CET ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
24-03-2017 08:00 CET ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan
23-03-2017 15:02 CET Report on Management's transactions with ALK-Abelló A/S B shares and associated securities
23-03-2017 14:44 CET Grant of share options and performance shares to members of the Board of Management and key employees
16-03-2017 12:55 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
15-03-2017 17:13 CET Annual General Meeting in ALK-Abelló A/S held on 15 March 2017
07-03-2017 15:43 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
06-03-2017 15:56 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
01-03-2017 23:02 CET ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
16-02-2017 08:27 CET ALK submits registration application for ragweed SLIT-tablet in Europe
14-02-2017 14:15 CET Annual General Meeting in ALK-Abelló A/S on 15 March 2017
07-02-2017 07:30 CET ALK releases its annual report 2016
30-01-2017 20:21 CET Release of annual report 2016 and audio cast
04-01-2017 08:51 CET ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales
22-12-2016 08:30 CET ALK strengthens its US presence through acquisition
14-12-2016 11:12 CET ALK – Financial calendar for the 2017 financial year